1.
Journal of International Oncology
;
(12): 545-547, 2016.
Article
in Chinese
| WPRIM
| ID: wpr-494855
ABSTRACT
Sorafenib is currently the only systematic molecular targeted drug approved by many coun-tries for the treatment of advanced HCC.But sorafenib limites has survival improvement,patients appear inevi-table disease progression soon.In recent years,Oxaliplatin-based regimens showed promising anti-tumor activi-ty,safety and low toxicities,which provides a new way for treatment of advanced HCC.